TricDB

midostaurin + chemotherapy

Drug Code : 2202132138
Drug Brand : Rydapt
Company : Novartis Pharmaceuticals
Approved by : NCCN
Approval Time :
Direct Target :
Drug Type : Combination
Gene : FLT3
Alteration : Codon 835 Missense
Indications :
Mechanism Of Action :
Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFRα/β, VEGFR2, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors. Midostaurin also demonstrated the ability to inhibit KIT signaling, cell proliferation and histamine release and induce apoptosis in mast cells.
Clinical Trial :
Efficacy & Safety :
Structure :
 Related Targets and Diseases
Drug Name Gene Disease Negative Genotypes Drug Brand Drug Type
Reference List :


Approval Notifications
Hot words
Terms of Use
Privacy Policy
biomeddb.org © 2025 Hubei University
Email: argyjbao@hotmail.com & skysky@hubu.edu.cn